Steve Schonfeld’s Janux Therapeutics JANX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$617K Buy
40,161
+27,822
+225% +$403K ﹤0.01% 1722
2026
Q1
$172K Sell
12,339
-33,114
-73% -$454K ﹤0.01% 1780
2025
Q4
$627K Buy
+45,453
New +$1.07M ﹤0.01% 1310
2025
Q1
Sell
-109,500
Closed -$5.86M 2351
2024
Q4
$5.86M Sell
109,500
-39,855
-27% -$2.11M 0.03% 452
2024
Q3
$6.79M Sell
149,355
-93,176
-38% -$4.05M 0.05% 427
2024
Q2
$10.2M Buy
242,531
+89,810
+59% +$4.22M 0.07% 343
2024
Q1
$5.75M Buy
+152,721
New +$3.33M 0.04% 591

Other funds holding JANX

Steve Schonfeld's JANX Position: Q2 2026 in Review

Steve Schonfeld increased its Janux Therapeutics (JANX) stake by 225% in Q2 2026, buying an estimated $403K and bringing the position to 40,161 shares worth $617K. The position accounts for ﹤0.01% of the portfolio, ranked #1722.

Steve Schonfeld first reported a position in JANX in Q1 2024 and has held it in 7 quarters since. The position peaked at $10.2M in Q2 2024. 196 funds tracked by Wall St. Rank hold JANX as of Q2 2026.

  • Steve Schonfeld held 40,161 shares of Janux Therapeutics worth $617K as of Q2 2026.
  • Steve Schonfeld bought 27,822 Janux Therapeutics shares in Q2 2026, an estimated $403K.
  • Janux Therapeutics made up ﹤0.01% of Steve Schonfeld's portfolio in Q2 2026, its #1722 holding.
  • Steve Schonfeld first reported a position in Janux Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Steve Schonfeld's Janux Therapeutics position peaked at $10.2M in Q2 2024.
  • 196 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.